Nextech Invest leads Series C round for Arvinas
New Haven, Connecticut-based Arvinas LLC, a developer of drugs based on protein degradation, has raised $55 million in Series C financing. Nextech Invest led the round with participation from other investors that included Deerfield Management, Hillhouse Capital, Sirona Capital, Canaan Partners, 5AM Ventures, RA Capital Management, OrbiMed and New Leaf Venture Partners. In addition to the funding, Dr. Jakob Loven, a partner at Nextech Invest, will join the Arvinas board of directors.
4 April 2018•1 min read
